



FOR IMMEDIATE RELEASE

Canadian Venture Exchange: FYT

FYTOKEM ANNOUNCES SENIOR MANAGEMENT CHANGE

Saskatoon, Saskatchewan, February 27, 2001 – Fytokem Products Inc. (Fytokem), a leading discoverer, developer and patentor of therapeutic plant extracts and bioactive molecules, today announced that its Vice-President of Research and Development, Mr. Mark Hetherington, will resign his position effective March 15, 2001.

Mr. Hetherington will continue to provide input to the Company's research effort on a full-time basis and will be actively involved in selecting and training his replacement while providing leadership to the laboratory staff during the transition period. As he begins a new and exciting role as Senior Research Officer for Prairie Plant Systems Inc. (Saskatoon), he will begin reducing his time commitment to Fytokem. Mr. Hetherington will remain an active Consultant to Fytokem's research effort and will provide guidance as a member of the Company's newly formed Scientific Advisory Committee.

"Mr. Hetherington has been an integral part of Fytokem since 1994. Not only did he make major contributions to our scientific abilities, he also did an excellent job of training his staff while he headed our research team. All of us at Fytokem wish him the greatest success in his future endeavors," said Art Hesje, President and CEO of Fytokem, "I expect to name a successor to Mr. Hetherington in the near future."

About Fytokem Products Inc.

Fytokem is a Saskatoon-based life sciences company engaged in the discovery of naturally occurring bioactive molecules for therapeutic use in both the cosmetic industry and their applications for the nutraceutical and pharmaceutical markets. The Company recently filed for patent protection for Oenothlein-B, a naturally occurring and complex molecule with remarkable anti-irritant, anti-inflammatory and free radical scavenging properties.

Through a strategic licensing agreement with Dragoco, Gerberding & Co. AG of Germany, Fytokem markets and sells high-value active ingredients such as Canadian Willowherb™, Tyrostat™, and Fytosorb™ to the Personal Care Industry.

Fytokem's common shares trade on the Canadian Venture Exchange under the symbol FYT; the Company has 12,451,957 shares outstanding.

The Canadian Venture Exchange has neither approved nor disapproved the information herein contained.

For more information, please contact:

Art Hesje
President and CEO
Fytokem Products Inc.
306-668-2552 tel.
306-978-2436 fax
ahesje@fytokem.com
www.fytokem.com

Wayne Hendry
Investor Relations
The Equicom Group Inc.
416-815-0700 ext. 238 tel.
416-815-0080 fax
whendry@equicomgroup.com
www.investorlook.com